Polimorfisme Gen DRD2 rs1799732 (-141c) Terhadap Terapi Aripiprazole pada Pasien Skizofrenia
Polymorphism Gene DRD2 rs1799732 (-141c) Against Aripiprazole Therapy In Schizophrenia Patients
DOI:
https://doi.org/10.25026/jsk.v4i2.783Keywords:
polymorphism, DRD2, aripiprazole, schizophrenia.Abstract
The polymorphism rs1799732 (-141C) is located in the 5 'promoter region of DRD2, where these SNPs can influence modulation of transcription activity and D2 receptor density. This study aims to provide a literature review of the polymorphism rs1799732 (-141C) because this gene polymorphism is the most common gene polymorphism in the world related to schizophrenia. This gene polymorphism is known to play a role in the variability of response to aripiprazole antipsychotic therapy in schizophrenic patients. The type of review used in this article is in the form of a literature review of 38 literature from various journals and textbooks. Schizophrenia is a disease that can affect the brain. In the brain there is a chemical delivery of messages that will forward messages around the brain. In schizophrenic patients, dopamine is excessive, while dopamine levels play an important role in feelings of pleasure and experiences of different moods. If dopamine levels are imbalanced, sufferers can experience both positive and negative symptoms. The hypothesis states that excessive dopaminergic activity can lead to schizophrenia. The dopaminergic system plays an important role as a modulator of affective and cognitive functions. Dopamine D2 receptor polymorphism is known to be a risk factor for schizophrenia. Polymorphisms are determinants of clinical symptoms and can play a role in the effectiveness and side effects of antipsychotics, including aripiprazole. Aripiprazole is a second-generation antipsychotic, an antipsychotic with partial agonist activity against dopamine D2.
References
WHO, 2019. Schizopherenia. Diakses pada tanggal 22 Juli melalui situs: https://www.who.int/topics/schizophrenia/en/).
Kementerian Kesehatan Republik Indonesia, 2016. Peranan Keluarga Dukung Kesehatan Jiwa Masyarakat. Jakarta. Diakses pada tanggal 22 Juli 2020 pada situs https://www.kemkes.go.id/article/print/16100700005/perankeluarga-dukungkesehatanjiwamas yarakat. Html #:~:text=Kesehatan% 20jiwa%20masih%20menjadi%20salah,47%2C5%20juta%20terkena%20dimensia.
Vijayan NN, Bhaskaran S, Koshy LV, Natarajan C, Srinivas L, Nair CM, Allencherry PM, Banerjee M. Association of Dopamine Receptor Polymorphisms with Schizophrenia and Antipsychotic Response in a South Indian Population, Behavioral and Brain Functions. 2007; 3:34.
Ye, J. et al. ‘Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment’, 13(April), pp. 1–9. doi: 10.3389/fnins. 2019.00355.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373. 2009. p: 31-41.
Bulayeva KB, Glatt SJ, Bulayev OA, Pavlova TA, Tsuang MT. Genome-wideLinkage Scan of Schizophrenia: A Crossisolate Study. Genomics. 2007 Feb; 89(2): 167-77.
Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010. 167, 763–772.
Arinami T, Gao M, Hamaguchi H, Toru M. A Functional Polymorphism in the Promoter Region of the Dopamine D2 Receptor Gene is Associated with Schizophrenia. Hum. Mol. Genet. 1997; 6: 577–582.
Breen G, Brown J, Maude S, et al. 141C ins/del polymorphism of the dopamine receptor 2 gene is associated with schizophrenia. in a British population. Am J Med Genet 1999; 88: 407–410.
Xiao.L, Functional -141C Ins/Del Polymorphism in The Dopamine Receptor Gene Promoter and Schizophrenia in a Chinese Han Population, Journal of International Medical Research. 2013;1171-1178.
Am J Psychiatry. Dopamine D2 receptor genetic variation and clinical response to antipsychotic drug treatment: A meta-analysis. 2010 July ; 167(7): 763–772.
Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system 11 interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav. 2008;13.
Sadock BJ, Sadock VA. Kaplan & sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Edisi 10. Philadelphia: Lippincott Williams & Wilkins; 2010
Neve KA, Seamans JK, Trantham-Davidson H. Dopamine Receptor Signaling, J Recept Signal Transduct Res. 2004; 24(3): 165-205.
Weyandt L. The Physiological Bases of Cognitive and Behavioral Disorders. New York: Routledge; 2006; 107-11 p.
Saiz.P.A., Garc? ?a-Portilla MP and Arango C. Genetic polymorphisms in the dopamine2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: data from an association study. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 26–31.
Gejman PV, Sanders A, Duan J. The Role of Genetics in the Etiology ofSchizophrenia. Psychiatr Clin North Am, 2010 Mar; 33: 35–66.
Murray RM, Lappin J, Di Forti M. Schizophrenia:From Developmental Deviance to Dopamine Dys regulation. Eur Neuropsycho pharmacol, 2008 Aug; 18 (3): S129-34.
He M, Yan H, Duan ZX, Qu W, Gong HY, Fan ZL, Kang JY, Li BC, Wang JM. Genetic Distribution and Association Analysis of DRD2 Gene Polymorphisms with Major Depressive Disorder in the Chinese Han Population, Int J Clin Exp Pathol. 2013; 6 (6): 1142-9.
Katzung BG. Basic & Clinical Pharmacology: Antipsychotic Agents & Lithium. 4th ed. New York: McGraw Hill; 2018. p. 511-31.
Wang, Y, Liu L, Xin L, Fan D,Ding N, Hu Y, Cai G, Wang L, Xia Q, Li X, Yang X, Zou Y, Pan F. The -141C Ins/Del and Taq1A Polymorphism in the Dopamine D2 Receptor Gene may confer Susceptibility to Schizophrenia in Asian Populations. Journal of Clinical Neuroscience. 2016; 30: 1-7.
Meidian, abdul chalik. Modul mata kuliah neurosains. Universitas Esa Unggul.2018.Diakses tanggal 11 Desember 2019 dari https://digilib.esaunggul.ac.id/public/UEU-Course-9732-Modul%20 Praktikum% 20FNS%20216%20Neurosains. Image. Marked. pdf.
Stoelting RK. Pharmacology and Physiology in Anesthetic Practice: Autonomic Nervous System. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 643-53.
Buchanan RW, Carpenter WT. Concept of Scizophrenia. Dalam : Sadock BJ, Sadock VA, eds. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. Edisi Kedelapan. Vol I. Philadelphia : Lippincott Williams & Willkins. 2005 : h. 1329 –44.
Buku Ajar Psikiatri. Badan Penerbit FK UI. Jakarta, 2013 pp. 173-198
Wells, et al. Pharmacotherapy Handbook 7th Edition. 2009. New York:McGraw-Hill.
Guyton dan Hall.Guyron and Hall Medical Physiology 12th Edition.2011. Philadephia: Elesevier.
Vanni N, InzerilloMT. Aripiprazole: a new antipsychotic agent with a unique mechanism of action. P&T.Vol. 28, No. 4. April 2003.
Bartolomeis AD, Tomasetti C, IasevoliF. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategiesbeyond Dopamine Receptor Antagonism, CNS Drugs. 2015; 29(9): 773–99.
Hertz MI, Marder SR. Schizophrenia. Comprehensive treatment and management. Philadelphia: Lippincott Williams & Wilkins, 2002.
Van Kammen DP, Marder SR. Serotonin-dopamine antagonist (atypical or second generation antipsychotics). In: Sadock BJ, Sadock VA, editors. Kaplan’s & Sadock’s comprehensive textbook of psychiatry. Volume I. 8th ed. Philadelphia: Lippincott Williams & Wilkins. 2005,p.2914-2937.
Schatzberg AF, Nemeroff CB. Textbook of psychopharmacology. 4th edition. American Psychiatric Publishing. 2009, p.716-28. 26.
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Limbroff DL, Ali MW. Efficacy and safety of aripiprazol and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:9, September 2002:763-76.
Regional Drug And Therapeutic Centre. Aripiprazole. New Drug Evaluation, No. 63, July 2004
Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and Safety of Aripiprazole vs. Haloperidol for Long-term Maintenance Treatment Following Acute Relapse of Schizophrenia,Int. J. Neuropsychopharmacol. 2003; 6, 325-37.
Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research. 2003; 61, 123-136.
Sadock VA. Kaplan & Sadocks’s Concise Textbook of Clinical Psychiatry:Schizophrenia. 3rd ed. Philadelphia: Lippincott Williams & Wilkins. 2008, p. 15677.
IMS Health. National Prescription Audit (NPA) and Total Patient Tracker (TPT). FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada). Diakses pada tanggal 22 Oktober 2020 dari situs : https://www.fda.gov/drugs/drug-safe ty-and-availability/fda-drug-safetyco mmunication-fda-warns-about-new-impulse-control-problems-associated -mental-health. 2016.
Kementerian Kesehatan Republik Indonesia, 2016. Peranan Keluarga Dukung Kesehatan Jiwa Masyarakat. Jakarta. Diakses pada tanggal 22 Juli 2020 pada situs https://www.kemkes.go.id/article/print/16100700005/perankeluarga-dukungkesehatanjiwamas yarakat. Html #:~:text=Kesehatan% 20jiwa%20masih%20menjadi%20salah,47%2C5%20juta%20terkena%20dimensia.
Vijayan NN, Bhaskaran S, Koshy LV, Natarajan C, Srinivas L, Nair CM, Allencherry PM, Banerjee M. Association of Dopamine Receptor Polymorphisms with Schizophrenia and Antipsychotic Response in a South Indian Population, Behavioral and Brain Functions. 2007; 3:34.
Ye, J. et al. ‘Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment’, 13(April), pp. 1–9. doi: 10.3389/fnins. 2019.00355.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373. 2009. p: 31-41.
Bulayeva KB, Glatt SJ, Bulayev OA, Pavlova TA, Tsuang MT. Genome-wideLinkage Scan of Schizophrenia: A Crossisolate Study. Genomics. 2007 Feb; 89(2): 167-77.
Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010. 167, 763–772.
Arinami T, Gao M, Hamaguchi H, Toru M. A Functional Polymorphism in the Promoter Region of the Dopamine D2 Receptor Gene is Associated with Schizophrenia. Hum. Mol. Genet. 1997; 6: 577–582.
Breen G, Brown J, Maude S, et al. 141C ins/del polymorphism of the dopamine receptor 2 gene is associated with schizophrenia. in a British population. Am J Med Genet 1999; 88: 407–410.
Xiao.L, Functional -141C Ins/Del Polymorphism in The Dopamine Receptor Gene Promoter and Schizophrenia in a Chinese Han Population, Journal of International Medical Research. 2013;1171-1178.
Am J Psychiatry. Dopamine D2 receptor genetic variation and clinical response to antipsychotic drug treatment: A meta-analysis. 2010 July ; 167(7): 763–772.
Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system 11 interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav. 2008;13.
Sadock BJ, Sadock VA. Kaplan & sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Edisi 10. Philadelphia: Lippincott Williams & Wilkins; 2010
Neve KA, Seamans JK, Trantham-Davidson H. Dopamine Receptor Signaling, J Recept Signal Transduct Res. 2004; 24(3): 165-205.
Weyandt L. The Physiological Bases of Cognitive and Behavioral Disorders. New York: Routledge; 2006; 107-11 p.
Saiz.P.A., Garc? ?a-Portilla MP and Arango C. Genetic polymorphisms in the dopamine2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: data from an association study. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 26–31.
Gejman PV, Sanders A, Duan J. The Role of Genetics in the Etiology ofSchizophrenia. Psychiatr Clin North Am, 2010 Mar; 33: 35–66.
Murray RM, Lappin J, Di Forti M. Schizophrenia:From Developmental Deviance to Dopamine Dys regulation. Eur Neuropsycho pharmacol, 2008 Aug; 18 (3): S129-34.
He M, Yan H, Duan ZX, Qu W, Gong HY, Fan ZL, Kang JY, Li BC, Wang JM. Genetic Distribution and Association Analysis of DRD2 Gene Polymorphisms with Major Depressive Disorder in the Chinese Han Population, Int J Clin Exp Pathol. 2013; 6 (6): 1142-9.
Katzung BG. Basic & Clinical Pharmacology: Antipsychotic Agents & Lithium. 4th ed. New York: McGraw Hill; 2018. p. 511-31.
Wang, Y, Liu L, Xin L, Fan D,Ding N, Hu Y, Cai G, Wang L, Xia Q, Li X, Yang X, Zou Y, Pan F. The -141C Ins/Del and Taq1A Polymorphism in the Dopamine D2 Receptor Gene may confer Susceptibility to Schizophrenia in Asian Populations. Journal of Clinical Neuroscience. 2016; 30: 1-7.
Meidian, abdul chalik. Modul mata kuliah neurosains. Universitas Esa Unggul.2018.Diakses tanggal 11 Desember 2019 dari https://digilib.esaunggul.ac.id/public/UEU-Course-9732-Modul%20 Praktikum% 20FNS%20216%20Neurosains. Image. Marked. pdf.
Stoelting RK. Pharmacology and Physiology in Anesthetic Practice: Autonomic Nervous System. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 643-53.
Buchanan RW, Carpenter WT. Concept of Scizophrenia. Dalam : Sadock BJ, Sadock VA, eds. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. Edisi Kedelapan. Vol I. Philadelphia : Lippincott Williams & Willkins. 2005 : h. 1329 –44.
Buku Ajar Psikiatri. Badan Penerbit FK UI. Jakarta, 2013 pp. 173-198
Wells, et al. Pharmacotherapy Handbook 7th Edition. 2009. New York:McGraw-Hill.
Guyton dan Hall.Guyron and Hall Medical Physiology 12th Edition.2011. Philadephia: Elesevier.
Vanni N, InzerilloMT. Aripiprazole: a new antipsychotic agent with a unique mechanism of action. P&T.Vol. 28, No. 4. April 2003.
Bartolomeis AD, Tomasetti C, IasevoliF. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategiesbeyond Dopamine Receptor Antagonism, CNS Drugs. 2015; 29(9): 773–99.
Hertz MI, Marder SR. Schizophrenia. Comprehensive treatment and management. Philadelphia: Lippincott Williams & Wilkins, 2002.
Van Kammen DP, Marder SR. Serotonin-dopamine antagonist (atypical or second generation antipsychotics). In: Sadock BJ, Sadock VA, editors. Kaplan’s & Sadock’s comprehensive textbook of psychiatry. Volume I. 8th ed. Philadelphia: Lippincott Williams & Wilkins. 2005,p.2914-2937.
Schatzberg AF, Nemeroff CB. Textbook of psychopharmacology. 4th edition. American Psychiatric Publishing. 2009, p.716-28. 26.
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Limbroff DL, Ali MW. Efficacy and safety of aripiprazol and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:9, September 2002:763-76.
Regional Drug And Therapeutic Centre. Aripiprazole. New Drug Evaluation, No. 63, July 2004
Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and Safety of Aripiprazole vs. Haloperidol for Long-term Maintenance Treatment Following Acute Relapse of Schizophrenia,Int. J. Neuropsychopharmacol. 2003; 6, 325-37.
Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research. 2003; 61, 123-136.
Sadock VA. Kaplan & Sadocks’s Concise Textbook of Clinical Psychiatry:Schizophrenia. 3rd ed. Philadelphia: Lippincott Williams & Wilkins. 2008, p. 15677.
IMS Health. National Prescription Audit (NPA) and Total Patient Tracker (TPT). FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada). Diakses pada tanggal 22 Oktober 2020 dari situs : https://www.fda.gov/drugs/drug-safe ty-and-availability/fda-drug-safetyco mmunication-fda-warns-about-new-impulse-control-problems-associated -mental-health. 2016.
Downloads
Published
2022-04-30
How to Cite
Fitri, F., Saleh, I., & Theodorus, T. (2022). Polimorfisme Gen DRD2 rs1799732 (-141c) Terhadap Terapi Aripiprazole pada Pasien Skizofrenia: Polymorphism Gene DRD2 rs1799732 (-141c) Against Aripiprazole Therapy In Schizophrenia Patients. Jurnal Sains Dan Kesehatan, 4(2), 214–221. https://doi.org/10.25026/jsk.v4i2.783
Issue
Section
Review
License
Copyright (c) 2022 Jurnal Sains dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
